Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2007

01-02-2007

Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

Authors: Dario Baratti, MD, Shigeki Kusamura, MD, Antonia Martinetti, MD, Ettore Seregni, MD, Daniela G. Oliva, MD, Barbara Laterza, MD, Marcello Deraco, MD

Published in: Annals of Surgical Oncology | Issue 2/2007

Login to get access

Abstract

Background

Recent phase I/II trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with PM undergoing CRS and IPHP.

Methods

Clinical data on 60 patients with PM operated with the intention to perform adequate CRS (residual tumor nodules ≤ 2.5mm) and IPHP were prospectively collected. Marker levels were determined pre-operatively, post-operatively, and routinely during long-term follow-up. Baseline diagnostic sensitivity, accuracy in monitoring response to treatment or tumor progression and prognostic significance were determined.

Results

Baseline diagnostic sensitivity was 53.3% for CA125, 0 for CEA, 3.8% for CA19.9 and 48.5% for CA15.3. Forty-six patients underwent adequate cytoreduction and IPHP; gross residual tumor was left after the operation in fourteen. Postoperatively, CA125 became negative in 21/22 patients with elevated baseline levels undergoing adequate CRS and IPHP, while remained elevated in 9/9 patients with persistent macroscopic disease. CA125 became positive in 12/12 patients with elevated baseline levels developing disease progression after adequate CRS and IPHP. Baseline CA125 showed borderline prognostic significance only among patients not previously treated with systemic chemotherapy.

Conclusions

CA125 was elevated in the majority of patients with PM in the present series. Serial maker measurements paralleled tumor growth or regression after CRS and IPHP, suggesting the need of further studies to assess the role of CA125 in this clinical setting.
Literature
1.
Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. JCO 1988; 6:147–153
2.
Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68:356–362PubMedCrossRef
3.
Eltabbakh GH, Piver MS, Hempling RE. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 1999; 70:6–12PubMedCrossRef
4.
Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am 2003; 12:703–727CrossRef
5.
Stewart JH, Perry S, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy:current status and future directions. Ann Surg Oncol 2005; 12:765–777PubMedCrossRef
6.
Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003; 83:147–53PubMedCrossRef
7.
Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6:582–590PubMedCrossRef
8.
Sebbag G, Yan H, Shmookler BM, et al. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87:1587–1593PubMedCrossRef
9.
Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67:999–1003PubMed
10.
Sugarbaker PH, Welch LS, Mohamed F, et al. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 2003; 12:605–621CrossRef
11.
Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21:4560–4567PubMedCrossRef
12.
Nonaka D, Kusamura S, Baratti D, et al. Diffuse malignant mesothelioma of the peritoneum. Cancer 2005; 104:2181–2188PubMedCrossRef
13.
Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405–412PubMedCrossRef
14.
Bagshawe KD, Rustin GJ. (1995) Circulating tumour markers. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford University Press, Oxford, UK, pp 412–420
15.
Weiss SW. World Health Organization Istological Classification of tomors. Histological typing of soft tissue tumours. 2nd edition. Berlin: Springer-Verlag, 1994
16.
Oken MM, Creech RH, Tormey, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655
17.
Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321–325
18.
Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58
19.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRef
20.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457–481
21.
Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220
22.
Hayes AJ, Mostyn-Jones A, Koban MU, et al. Serum vascolar growth factor as a tumor marker in soft tissue sarcoma. Br J Surg 2004; 91:242–247PubMedCrossRef
23.
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362:1612–1616PubMedCrossRef
24.
Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma and serum osteopontin level. N Engl J Med 2005; 353:1564–1573PubMedCrossRef
25.
Hedman M, Arnberg H, Wernlund J, et al. Tissue polypeptide antigen (TPA), hyaluronian and CA125 as serum markers in malignant mesothelioma. Anticancer Res 2003, 23:531–536PubMed
26.
Simsek H, Kadayifci A, Okan E. Importance of serum CA125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996; 17:1–4PubMedCrossRef
27.
Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68:1331–1337PubMedCrossRef
28.
Rustin GJS, Timmers P, Nelstrop P, Shreeves G, Bentzen SM, Baron B, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide Journal of Clinical Oncology 2006; 24:45–51PubMedCrossRef
29.
Kerin MJ, McAnena OJ, O’Malley VP, et al. CA15–3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg 1989; 76:838–839PubMedCrossRef
30.
Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22:1203–1214PubMedCrossRef
31.
Bateman AC, al-Talib RK, Newman Y, et al. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997; 30:49–56PubMedCrossRef
32.
Duan HJ, Itoh N, Yamagami O, et al. Diffuse malignant peritoneal mesothelioma in a young woman with a high serum level of CA125. Acta Pathol Jpn 1991; 41:158–163PubMed
33.
Almudevar Bercero E, Garcia-Rostan Perez GM, Garcia Bragado F, et al. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31:267–273PubMedCrossRef
34.
Kebapci M, Vardareli E, Adapinar B, et al. CT findings and serum CA125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature. Eur Radiol 2003; 13:2620–2626PubMedCrossRef
35.
Begent R, Rustin GJ. Tumour markers: from carcinoembryonic antigen to products of hybridoma technology. Cancer Surv 1989; 8:107–21PubMed
36.
Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961–967PubMedCrossRef
37.
Garcia-Carbonero R, Paz-Arez L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676–681PubMedCrossRef
Metadata
Title
Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
Authors
Dario Baratti, MD
Shigeki Kusamura, MD
Antonia Martinetti, MD
Ettore Seregni, MD
Daniela G. Oliva, MD
Barbara Laterza, MD
Marcello Deraco, MD
Publication date
01-02-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9192-8

Other articles of this Issue 2/2007

Annals of Surgical Oncology 2/2007 Go to the issue

OriginalPaper

Sentinel Node Biopsy and Concomitant Probe-Guided Tumor Excision of Nonpalpable Breast Cancer

OriginalPaper

Asymptomatic Colorectal Cancer with Un-Resectable Liver Metastases: Immediate Colorectal Resection or Up-Front Systemic Chemotherapy?

OriginalPaper

Local/Cervical Block Anesthesia versus General Anesthesia for Minimally Invasive Parathyroidectomy: What are the Advantages?

OriginalPaper

Disparities in Colon Cancer Presentation and In-Hospital Mortality in Maryland: A Ten-Year Review

OriginalPaper

Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer

OriginalPaper

Incidence and Treatment of Tracheal Cancer: A Nationwide Study in The Netherlands